J&J adds PhI­II hy­per­ten­sion drug to the pipeline with $230M-plus cash deal for Idor­sia

J&J is adding a $230 mil­lion bonus deal to its $30 bil­lion buy­out of Acte­lion.

The phar­ma gi­ant just snagged com­mer­cial­iza­tion rights on aproci­ten­tan (ACT-132577), which scored promis­ing Phase II da­ta for treat­ment re­sis­tant hy­per­ten­sion. Poised at the launch of a Phase III tri­al, J&J is hand­ing over $160 mil­lion in cash and will fol­low up with a se­ries of pay­ments with the rest com­ing in in­stall­ments over the next three and a half years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.